AstraZeneca Results Presentation Deck
November 2024, 38 slides
  1. AstraZeneca
  2. Related Decks
  3. Results Presentation Decks
and results conference call and for investors and analysts | AstraZeneca
forward looking statements in order among other things to the safe harbour provisions of the us private securities litigation reform act of hereafter the group provides the following cautionary statement this document contains certain forward looking statements with respect to the operations performance and financial condition of the group including among other things statements about expected revenues margins earnings per share or other financial or other measures although the group believes its expectations are based on reasonable assumptions any forward looking statements by their very nature involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted the forward looking statements reflect knowledge and information available at the date of preparation of this document and the group undertakes no obligation to update these forward looking statements the group identifies the forward looking statements by using the words anticipates believes expects intends and similar expressions in such statements important factors that could cause actual results to differ materially from those contained in forward looking statements certain of which are beyond the group control include among other things the risk of failure or delay in delivery of pipeline or launch of new medicines the risk of failure to meet regulatory or ethical requirements for medicine development or approval the risk of failures or delays in the quality or execution of the group commercial strategies the risk of pricing access and competitive pressures the risk of failure to maintain supply of compliant quality medicines the risk of illegal trade in the group medicines the impact of reliance on third party goods and services the risk of failure in information technology or the risk of failure of critical processes the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives the risk of failure to attract develop engage and retain a diverse talented and capable the risk of failure to meet regulatory or ethical expectations on environmental impact including climate change the risk of the safety and efficacy of marketed medicines being questioned the risk of adverse outcome of litigation and or governmental investigations intellectual property related risks to the group products the risk of failure to achieve strategic plans or meet targets or expectations the risk of failure in financial control or the occurrence of fraud the risk of unexpected deterioration in the group financial position the impact that global and or geopolitical events may have or continue to have on these risks on the group ability to continue to mitigate these risks and on the group operations financial results or financial condition nothing in this document or any related presentation should be construed as a profit forecast | AstraZeneca
and results conference call agenda opening remarks financial results oncology dobber rare disease marc closing remarks a | AstraZeneca
opening remarks | AstraZeneca
strong underlying performance in and double digit total revenue and core growth and prior year double digit growth across focus therapy areas prior year total revenue core upgraded guidance total revenue and core expected to increase by high teens percentage | AstraZeneca
benefitting from global presence of growing portfolio double digit growth across us and with broad based distribution of total revenue us china | AstraZeneca
multiple high value phase in laura expanding as backbone in early stage echo first to show overall survival trend amplify securing leadership with finite treatment option destiny breast moving into benefit in her first and only to show survival benefit in first regimen to extend survival in muscle invasive bladder cancer first to show benefit in nasal polyps adult extends strong clinical benefit to adult patient population with high unmet need indication expansion opportunities above represent combined pyr | AstraZeneca
financial results | AstraZeneca
global demand growth across leading medicines top medicines by total revenue strong product sales and alliance revenue momentum through a cox be | AstraZeneca
and reported profit and loss | AstraZeneca
and core profit and loss | AstraZeneca
upgrading guidance net cash inflow from operating activities increased in net debt bridge guidance upgraded given strong performance and increased confidence in achieving certain sales milestones guidance is upgraded total revenue anticipated to increase by a high teens percentage core anticipated to increase by a high teens percentage other elements of the income statement are expected to be broadly in line with the indications issued in the company earnings statement net debt adjusted anticipated impact low single digit adverse impact on total revenue and mid single digit impact on core | AstraZeneca
oncology | AstraZeneca
oncology and total revenue in driven by global demand for key medicines oncology key dynamics strong demand across indications and lengthening dot sustained leadership in demand growth in us and continued impact demand from in us in sustained leadership driven by us and established soc in her and her low encouraging early adoption in agnostic new market leader in altered population new indications us laura and duo her gastric and her other regulatory us priority review echo gall a | AstraZeneca
oncology highlights continuing momentum across oncology with data at key medical congresses in and expanding into bladder cancer and advancing next gen and advancing with upcoming data at ash only regimen to show benefit potential new soc patients amplify fixed duration in clinically meaningful improvement trend to benefit ineligible phase next wave in house novel high rate in high levels of complete remission in good tolerability | AstraZeneca
oncology highlights reinforcing leadership in with novel treatment approaches established backbone treatment for novel combinations extend use across multiple lines of therapy early stage laura line line aura and saffron convenient all oral regimen lung lung lung submission later line lung withdrawn | AstraZeneca
dobber | AstraZeneca
and total revenue strong growth across i and i i key dynamics | AstraZeneca
highlights multiple high potential and novel combinations to drive next wave of growth cardiovascular renal metabolism advancing next generation medicines established with key foundational medicines leveraging new mechanisms to expand existing focus pursuing novel combinations to target complex conditions and address of disease | AstraZeneca
highlights positive phase trial reinforces first in class mechanism of action phase trial met both primary in chronic and nasal polyps multiple indication expansion opportunities significant patient burden in patients with nasal polyps impact on quality of life need for surgery and systemic steroids placebo statistically significant clinically meaningful reduction in size of nasal polyps nasal congestion million patients treated for nasal polyps million with uncontrolled nasal polyps direction severe asthma china primary met crossing eosinophilic esophagitis new phase initiating billion opportunity | AstraZeneca
rare disease marc | AstraZeneca
rare disease and total revenue in driven by continued neurology growth rare disease key dynamics franchise sustainable durable growth driven by demand growth in neurology indications continued conversion to partly offset by growth in emerging markets beyond complement market expansion and increased demand and driven by continued global demand | AstraZeneca
rare disease highlights expanding the potential of to adult patients with a progressive genetic condition phase trial improvement in adult patients by benign that develop on nerve sheaths leads to disfigurement motor dysfunction and pain us primary met statistically significant clinically meaningful volume reduction encouraging effect across pain severities low discontinuation rates rapid efficacy onset has the potential to address the high unmet need in adult patients with | AstraZeneca
closing remarks | AstraZeneca
catalyst rich path through with potential to unlock significant value through and beyond indication expansion key opportunities disruptive technologies her cell therapy and phase i multiple bladder trials in house phase i and phase i calypso weight management phase i pipeline momentum supports ambition to achieve in total revenue by | AstraZeneca
on track to deliver on strategic ambitions ambition to deliver in total revenue by on track to deliver mid core operating margin by beyond core operating margin will be influenced by portfolio evolution and the company will target at least mid ambition to deliver at least by delivered to date | AstraZeneca
a session marc dobber | AstraZeneca
appendix glossary glossary oncology maps key medicines performance by therapy area | AstraZeneca
glossary abbreviations | AstraZeneca
in lung cancer ambition for of lung cancer patients to be eligible for medicine by leading the future of lung cancer treatment establishing as backbone in leading in advancing best in class to replace systemic chemotherapy delivering next wave to improve on developing novel combinations including investing behind new technologies and platforms including cell therapy and testing screening | AstraZeneca
in breast cancer ambition to eliminate breast cancer as a cause of death | AstraZeneca
oncology | AstraZeneca
oncology | AstraZeneca
oncology | AstraZeneca
cardiovascular renal metabolism | AstraZeneca
respiratory immunology | AstraZeneca
respiratory immunology | AstraZeneca
rare disease | AstraZeneca
See More
AstraZeneca
Results Presentation Decks
Drug Manufacturers—General Decks
Healthcare Decks
Explore Topics
Medicine
Oncology
Cancer
Rare disease
Recent decks by AstraZeneca
Results
November 2024
Investor Event
September 2024
Results
February 2024
Investor Conference
January 2024
See all presentations by AstraZeneca (30 decks)
Related decks
Nuvectis Pharma
Investor Presentation
August 2023
Invitae
Results
August 2023
Exscientia
Results
November 2023
Nuvectis Pharma
Investor Presentation
July 2023
Nuvectis Pharma
Investor Presentation
December 2023
23andMe
Investor Presentation
April 2023
Alkermes
Investor Day
March 2021
BioNTech
Results
November 2020
Recent decks by AstraZeneca
See all presentations (30 decks)
Results
November 2024
Investor Event
September 2024
Results
February 2024
Investor Conference
January 2024
Nuvectis Pharma
Investor Presentation
August 2023
Invitae
Results
August 2023
Exscientia
Results
November 2023
Nuvectis Pharma
Investor Presentation
July 2023
Nuvectis Pharma
Investor Presentation
December 2023
23andMe
Investor Presentation
April 2023
Alkermes
Investor Day
March 2021
BioNTech
Results
November 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io